Will play a key role in management team, ensuring NattoPharma delivers according to its strategy and business goals.
Oslo, Norway and Edison, NJ (5 November 2019) — NattoPharma ASA is looking for an ambitious commercial CFO to further develop the financial platform of the company. The CFO will play a key role in the management team, working closely with the CEO, ensuring that NattoPharma is delivering according to its strategy and its business ambitions.
The new CFO will be a driving force to the financial and economic development of NattoPharma ASA, and will be responsible for the financial monitoring, control and reporting, and managing the financial forecasting and budgets. Based on a modern digitized platform, the CFO will build and strengthen all the financial processes, as well as the internal routines and policies of the business. NattoPharma is a growing company and the new CFO will have the actively participate in the company’s overall development, including supply chain improvements.
You could be a fit for our position if you are an ambitious, operational- and business-oriented economist who sees the potential and opportunities that lie within the company and the market. An ideal candidate would have a master’s degree in accounting / finance, minimum 5 years relevant work-experience as controller, financial manager or CFO, and some experience from a listed company. While international experience, as well as from a matrix organization, is an advantage, profound knowledge of and experience with Norwegian tax system and laws is requirement for this position.
NattoPharma offers a dynamic environment within a fast-growing industry where you can expect to be able to put your fingerprint on the next step in the company’s development. The position will be reporting to the CEO and the workplace will be Lysaker, Oslo.
Questions can be directed to Visindi; Monica Strysse mobile + 47 971 00 769 or Magne Amundsen mobile +47 916 56 101. Apply through https://visindi.no/en/vacancies.
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the supplement industry world leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements, in addition to exclusive access to the research efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of the pharmaceutical domain. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.
For more information, please contact:
Kate Quackenbush, NattoPharma Director of Communications
P: 609-643-0749 x 220; E: email@example.com